Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

Parkinson's disease (PD) is slowly progressing neurodegenerative disorder that affects millions of patients worldwide. While effective symptomatic therapies for PD exist, there is no currently available disease modifying agent to slow or stop the progression of the disease. Many years of research from various laboratories around the world have provided evidence in favor of the potential ability of GM1 ganglioside to be a disease modifying agent for PD. In this paper, information supporting the use of GM1 as a disease modifying therapeutic for PD is reviewed along with information concerning the role that deficiencies in GM1 ganglioside (and potentially other important brain gangliosides) may play in the pathogenesis of PD. © 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.


J S Schneider. A critical role for GM1 ganglioside in the pathophysiology and potential treatment of Parkinson's disease. Glycoconjugate journal. 2022 Feb;39(1):13-26

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 34037912

View Full Text